The weekly litigation news digest is live. Subscribe now

IP Verse

Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9) - EP4252857

The patent EP4252857 was granted to Regeneron Pharmaceuticals on Sep 25, 2024. The application was originally filed on Sep 12, 2012 under application number EP23176223A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP4252857

REGENERON PHARMACEUTICALS
Application Number
EP23176223A
Filing Date
Sep 12, 2012
Status
Granted And Under Opposition
Aug 22, 2024
Publication Date
Sep 25, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

AMGENJun 23, 2025BIJVANKADMISSIBLE

Patent Citations (11) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2010166768
DESCRIPTIONUS6596541
OPPOSITIONEP2756004
OPPOSITIONEP3536712
OPPOSITIONUS2010166768
OPPOSITIONWO2009026558
OPPOSITIONWO2010077854
OPPOSITIONWO2012154999
OPPOSITIONWO2013016648
OPPOSITIONWO2015054619
SEARCHWO2011028938

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents